Oxalate buildup triggers systemic inflammation and cardiac damage, study shows

by Max Delbrück Center for Molecular Medicine

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

People with chronic kidney disease (CKD) have a significantly increased risk of death from cardiovascular disease. They also suffer from chronic inflammation, the causes of which are still only partly understood. Oxalic acid (oxalate) has so far been known primarily for its role in the formation of kidney stones. The molecule is a natural metabolic byproduct, is found in certain foods and is normally excreted by the kidneys in urine. However, when kidney function is impaired, oxalate accumulates in the body and can promote inflammatory processes.

The Experimental Biomedicine II department at Würzburg University Hospital (UKW), together with the Experimental and Clinical Research Center (ECRC), a joint institution of Charité—Universitätsmedizin Berlin and the Max Delbrück Center, investigated the immunological mechanisms linking oxalate-induced kidney damage with systemic inflammation and cardiovascular injury.

"In our research project, an oxalate-enriched diet activated the immune system systemically in mice. In other words, inflammatory processes spread throughout the body. This led not only to kidney damage, but also to pathological changes in the heart that reduced cardiac function," says Dr. Hendrik Bartolomaeus. The scientist, who is part of Professor Alma Zernecke-Madsen's team at UKW, shares senior authorship of the study with Dr. Nicola Wilck of ECRC. The study was published in Cardiovascular Research. Bartolomaeus previously worked in Wilck's laboratory.

More oxalate, more pro-inflammatory immune cells

The team identified the cytokine interleukin-17A (IL-17A) as a key factor. IL-17A is produced by certain immune cells and can amplify inflammation. The researchers found that oxalate promoted IL-17A production and disrupted the energy metabolism of immune cells. Elevated IL-17A levels were also detected in patients with the rare inherited metabolic disorder primary hyperoxaluria, in which enzyme defects cause the liver to produce too much oxalate.

The team also investigated what happens when IL-17A is specifically blocked. "In the animal model, several signs of disease improved simultaneously," says Wilck. "The mice's kidneys functioned better, inflammation and fibrosis declined, and heart damage was reduced. We therefore describe a potentially targetable therapeutic axis: oxalate–IL-17A–cardiorenal injury." The study thus mechanistically links elevated oxalate levels with IL-17A-mediated inflammation, cellular metabolism and cardiorenal organ damage.

"Overall, our results show that oxalate not only damages the kidneys, but also contributes to cardiovascular disease through IL-17A and inflammatory processes," adds first author Moritz Wimmer from the ECRC. "Oxalate can therefore no longer be viewed solely as a crystal-forming substance that locally damages the kidneys. Rather, it represents a systemic burden on the immune system and metabolism."

New prospects for anti-inflammatory therapies

Clinically, this means that elevated oxalate levels may not only burden the kidneys, but also directly affect the cardiovascular system through inflammatory processes. The work could therefore help identify patients with kidney disease at particularly high cardiovascular risk, enable more targeted interpretation of biomarkers and support the development of new anti-inflammatory therapeutic strategies.

What comes next? Co-authors Professor Felix Knauf and his team at Charité—Universitätsmedizin Berlin and the Mayo Clinic have already shown in large patient cohorts that oxalate levels are often elevated in people with impaired kidney function. High oxalate levels were also associated with an increased risk of cardiovascular complications.

The researchers now plan to investigate whether the inflammatory mechanisms they identified can also be detected in larger cohorts of patients with CKD. They are analyzing data on systemic inflammation, CKD progression and cardiovascular complications. "A key question will be to what extent the observed IL-17A-mediated inflammatory axis is specific to oxalate. Similar mechanisms may also contribute to cardiovascular damage in other causes of kidney disease," says Bartolomaeus.

Wilck adds, "In the long term, we want to better understand which inflammatory pathways in chronically damaged kidneys can be targeted therapeutically and which patients are most likely to benefit."

Publication details

Moritz I Wimmer et al, Interleukin-17A mediates cardiorenal injury in oxalate nephropathy, Cardiovascular Research (2026). DOI: 10.1093/cvr/cvag158

Journal information: Cardiovascular Research

Key medical concepts

Chronic Kidney DiseaseIL17A protein, human

Clinical categories

NephrologyCardiologyAllergy and immunology Provided by Max Delbrück Center for Molecular Medicine Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Oxalate buildup triggers systemic inflammation and cardiac damage, study shows (2026, July 10) retrieved 11 July 2026 from https://medicalxpress.com/news/2026-07-oxalate-buildup-triggers-inflammation-cardiac.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.